Filing excerpt
On January 15, 2026, we announced our entry into a definitive agreement to acquire 100 percent of Penumbra, Inc. (Penumbra), a publicly traded medical technology company primarily focused on innovative medical thrombectomy products for use in peripheral vascular procedures in the removal of blood clots and blockages.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
sec-10kcapexIncreaseGet every 10-K signal for Boston Scientific and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Boston Scientific this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/12ec121e-c8b4-4f2d-bd1e-680e3fe86889 returns this record as JSON. POST /v1/companies/enrich returns every signal for bostonscientific.com.
{
"signal_id": "12ec121e-c8b4-4f2d-bd1e-680e3fe86889",
"signal_type": "sec-10k",
"signal_subtype": "capexIncrease",
"detected_at": "2026-02-24T09:19:12.736+00:00",
"company": {
"name": "Boston Scientific",
"domain": "bostonscientific.com"
},
"data": {
"detail": "This massive acquisition, expected to close in 2026, will require significant integration efforts across IT, finance, and operations, creating opportunities for consulting, systems integration, and other post-merger services.",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Total purchase price for the acquisition of Penumbra, Inc.",
"dollar_millions": 14500
},
"summary": "Announced definitive agreement to acquire Penumbra, Inc. for $14.5 billion in 2026",
"excerpts": "On January 15, 2026, we announced our entry into a definitive agreement to acquire 100 percent of Penumbra, Inc. (Penumbra), a publicly traded medical technology company primarily focused on innovative medical thrombectomy products for use in peripheral vascular procedures in the removal of blood clots and blockages.",
"relevance": 1,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/bsx-20251231.htm",
"filing_date": "2026-02-17",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Budget available",
"signal_category": "financial",
"technologies_mentioned": [
"Computer Assisted Vacuum Thrombectomy (CAVT™)"
]
}
}
curl https://signals.autobound.ai/v1/signals/12ec121e-c8b4-4f2d-bd1e-680e3fe86889 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bostonscientific.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.